NVP-TAE684-resistant ALK mutants [plasma membrane]

Stable Identifier
R-HSA-9700568
Type
Set [DefinedSet]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
21948233 ALK mutations conferring differential resistance to structurally diverse ALK inhibitors

Lovly, CM, Grütter, C, Heynck, S, Sos, ML, Thomas, RK, Peifer, M, Balke-Want, H, Heuckmann, JM, Rauh, D, Koker, M, Weiss, J, Pao, W, Hölzel, M

Clin. Cancer Res. 2011
18923525 Activating mutations in ALK provide a therapeutic target in neuroblastoma

Zozulya, S, George, RE, Gilliland, DG, Morris, SW, Luther, W, London, WB, Hanna, M, Meyerson, M, McGrady, P, Sanda, T, Gregor, VE, Look, AT, Zhang, J, Fröhling, S, Ahn, Y, Diller, L, Webb, TR, Zhou, W, Greulich, H, Gray, NS, Xue, L

Nature 2008
27009859 TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors

Gokhale, V, Groysman, MJ, Pongtornpipat, P, Wang, M, Tapia, EO, Rajan, SS, Amin, AD, Schatz, JH, Li, L

Oncotarget 2016
23239810 Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

Ceccon, M, Mologni, L, Scapozza, L, Bisson, W, Gambacorti-Passerini, C

Mol. Cancer Res. 2013
21791641 A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

Zheng, W, Lindeman, N, Capelletti, M, Gray, NS, Wong, KK, Christensen, JG, Ercan, D, Jänne, PA, Rodig, SJ, Shimamura, T, Nikiforow, S, Weremowicz, S, Sasaki, T, Okuda, K, Wilner, K, Eck, MJ, Butaney, M, Stumpfova, M, Yanagita, M, Heon, S, Ogino, A, Xiao, Y, Marcoux, JP, Koivunen, J, Lathan, C, Du, J

Cancer Res. 2011
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!